ACADIA Pharmaceuticals Inc. (ACAD): What’s Next For This Biotech?

Page 1 of 2

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) 1,100% gain makes it one of the best performing stocks in the market. This rally began after its Parkinson’s disease drug Pimavanserin produced a positive outcome in its Phase III trial.

In particular, Pimavanserin had no negative impact on motor function and significantly reduced psychotic episodes compared to placebo. The drug’s likelihood for approval is now all but a guarantee, and investors are buying like crazy.

ACADIA Pharmaceuticals Inc. (ACAD)

Moreover, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) does not have to complete another late-stage study, as previously expected. This fact has created much of the gains following its initial 150% pop in November 2012. Therefore, it is expected that Pimavanserin will be approved by early next year and then available in the market in late 2014 or early 2015.

In terms of upside, Pimavanserin’s expected sales for the Parkinson’s disease Psychosis indication is between $300 and $400 million annually. The real upside for Pimavanserin lies in off-label uses and its expanded use. Most believe that it will be used in schizophrenia, bipolar disorder, and other diseases where antipsychotics are necessary. Thus, ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is poised to benefit from a large $18 billion market, and many have projected that Pimavanserin’s label and off-label uses combined could generate sales north of $1 billion annually.

What To Do Next

As a long-term investment, I think ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) is one of the best places to put money to work in the market. As a short-term investment, its stream of catalysts are running low.

Acadia has seen its large run-up because of how cheap it was prior to Pimavanserin’s data. Now, with a $1.25 billion market cap, the only catalyst remaining is its meeting with the FDA and the eventual launch.

While these two events are important, 16 months of inactivity and a lack of headlines can hurt a biotechnology stock. Also, during the launch and approval process, sometimes warnings and negative information is found that was previously undiscovered.

Thus, stocks that run higher before these events, often trade lower as all good news is already priced into the stock. Therefore, if you own ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) with gains of 300% plus, it might be wise to take some profits off the table – especially if you’re not planning to hold the stock for multiple years.

The Only Likely Catalyst

While the catalysts will be few and far between over the next 16 months, there is one possible catalyst remaining, and that is an acquisition.

Like I said, the antipsychotic market is massive, and one where most large pharma companies have drugs available. However, many of these antipsychotic drugs are being replaced with newer and better drugs, along with losing patent protection.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) has full rights to Pimavanserin, and with it being an innovating drug with large potential sales, it seems logical that large pharma would show a considerable amount of interest. If in fact the company is for sale and the large pharma company has an antipsychotic segment.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

50 Crazy Facts About Japan You Won’t Believe

Top 10 Least Expensive Hybrid Cars to Save the Planet With

The 10 Biggest ‘Gate’ Controversies in History

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!